Shares of Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) have earned an average rating of “Buy” from the twelve ratings firms that are currently covering the firm. Five equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $18.11.

Several research analysts have recently commented on SCMP shares. Roth Capital reissued a “buy” rating on shares of Sucampo Pharmaceuticals in a research note on Tuesday, July 12th. Maxim Group reissued a “buy” rating on shares of Sucampo Pharmaceuticals in a research note on Monday, July 11th. Northland Securities assumed coverage on shares of Sucampo Pharmaceuticals in a research note on Wednesday, September 7th. They issued an “outperform” rating and a $15.00 price objective for the company. Vetr upgraded shares of Sucampo Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $14.00 price target for the company in a research note on Thursday, September 29th. Finally, Jefferies Group lowered their price target on shares of Sucampo Pharmaceuticals from $16.00 to $14.00 and set a “hold” rating for the company in a report on Thursday, August 4th.

Several hedge funds have recently added to or reduced their stakes in SCMP. BlackRock Fund Advisors increased its stake in Sucampo Pharmaceuticals by 3.1% in the first quarter. BlackRock Fund Advisors now owns 1,630,036 shares of the biopharmaceutical company’s stock worth $17,816,000 after buying an additional 48,420 shares during the last quarter. Quantbot Technologies LP increased its stake in Sucampo Pharmaceuticals by 850.4% in the second quarter. Quantbot Technologies LP now owns 14,903 shares of the biopharmaceutical company’s stock worth $163,000 after buying an additional 13,335 shares during the last quarter. Princeton Alpha Management LP bought a new stake in Sucampo Pharmaceuticals during the second quarter worth $138,000. Spark Investment Management LLC increased its stake in Sucampo Pharmaceuticals by 120.7% in the first quarter. Spark Investment Management LLC now owns 140,388 shares of the biopharmaceutical company’s stock worth $1,534,000 after buying an additional 76,788 shares during the last quarter. Finally, Boston Partners increased its stake in Sucampo Pharmaceuticals by 36.6% in the second quarter. Boston Partners now owns 238,519 shares of the biopharmaceutical company’s stock worth $2,617,000 after buying an additional 63,965 shares during the last quarter. 40.64% of the stock is owned by institutional investors and hedge funds.

Shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) opened at 12.80 on Tuesday. The stock has a market capitalization of $547.97 million, a P/E ratio of 44.91 and a beta of 1.57. Sucampo Pharmaceuticals has a 12-month low of $9.59 and a 12-month high of $21.27. The stock has a 50 day moving average of $12.35 and a 200 day moving average of $11.55.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported $0.23 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.22 by $0.01. Sucampo Pharmaceuticals had a net margin of 6.65% and a return on equity of 42.18%. The business earned $52 million during the quarter, compared to analyst estimates of $48.33 million. During the same quarter last year, the firm posted $0.21 earnings per share. The business’s revenue for the quarter was up 49.1% compared to the same quarter last year. Equities research analysts anticipate that Sucampo Pharmaceuticals will post $1.03 EPS for the current fiscal year.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It operates through development and commercialization of pharmaceutical products segment. Its operations are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts operations in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, the United Kingdom.

5 Day Chart for NASDAQ:SCMP

Receive News & Stock Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.